News and trends on diagnostics testing, insurance coverage, and reimbursement.
Palmetto's MolDx has agreed to cover Myriad's MyPath Melanoma to help rule out the disease when the biopsy can't be definitively classified by standard clinical and histopathological characteristics.
The agency said it is sensitive to stakeholder concerns and is working with MACs to adjust claims processing systems.
The test is designed to determine which early-stage, estrogen receptor-positive breast cancer patients are likely to benefit from extended endocrine therapy.
The LCD will enable coverage of Envisia in patients for whom imaging does not lead to a definitive diagnosis of idiopathic pulmonary fibrosis.
The diversity of the organizations that have signed the letter to CMS demonstrates widespread concern over this policy.
Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.
A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.
At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.
In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.